Impact of the COVID-19 pandemic on the pharmacological, physical, and psychological treatments of pain: findings from the Chronic Pain & COVID-19 Pan-Canadian Study : PAIN Reports

Journal Logo

COVID-19 and pain

Impact of the COVID-19 pandemic on the pharmacological, physical, and psychological treatments of pain: findings from the Chronic Pain & COVID-19 Pan-Canadian Study

Lacasse, Anaïsa,*; Pagé, M. Gabrielleb,c; Dassieu, Liseb; Sourial, Nadiab,d; Janelle-Montcalm, Audréeb; Dorais, Marce; Nguena Nguefack, Hermine Lorea; Godbout-Parent, Mariméea; Hudspith, Mariaf; Moor, Greggf; Sutton, Kathrynf; Thompson, James M.g,h; Choinière, Manonb,c

Author Information
doi: 10.1097/PR9.0000000000000891
  • Open

1. Introduction

The first Canadian case of COVID-19 was reported in January 2020.8 Community transmission was confirmed in March 2020, and rapid closure of daycares, schools, workplaces, and nonessential services occurred to varying degrees across the Canadian provinces and territories.7,32 Restrictions to private and public gatherings in addition to closure of regional/provincial/national/international borders were also put in place. The biopsychosocial effects of the COVID-19 pandemic are important in the general population50,54 and affect disproportionately high-risk and vulnerable individuals such as those living with chronic diseases, older adults, and socially and economically deprived populations.9,52 Public health restrictions and pandemic-related stress thus added to the preexisting physical, psychosocial, and financial burden that is known to be associated with chronic pain (CP).14,66 Moreover, persistent users of prescribed opioids have been identified as a vulnerable group in the COVID-19 pandemic because the context makes it difficult to adhere to all prescribing and follow-up opioid guidelines.39 Opioids have also been shown to weaken the immune system.57

Multimodal treatment is recognized as the optimal paradigm for the management of CP.10 A careful balance between pharmacological and physical/psychological approaches is therefore desirable, but it can be hard to achieve and easily disrupted.3,12 Since the beginning of the pandemic, many challenges led us to believe that the pharmacological treatment of CP would be substantially impacted. Case in point, uncertainty regarding the use of nonsteroidal anti-inflammatory drugs during the pandemic29,59 was broadcast throughout the media in March 2020, which might have sparked concerns among patients and prescribers. Also, in some health care jurisdictions, patients living with certain arthritic conditions (eg, rheumatoid arthritis, erosive osteoarthritis of the hands) were denied hydroxychloroquine/chloroquine treatment in an effort to prevent a shortage of these drugs31 because these antimalarial were initially examined as a treatment for COVID-19.17,53 Shortages of opioids were also announced by some Canadian Health Technology Assessment agencies in early June 2020.30 The demand for dexamethasone also peaked when it was suggested to be an effective treatment for COVID-19 in June 2020.41 Furthermore, many multidisciplinary pain treatment clinics were closed or reduced their services.14,40 The confinement measures along with personal financial losses may also have limited access to many other types of treatments (eg, physical therapy, psychological counselling, and self-help groups).14,33 Finally, fear of going to health care appointments14 and nonmedical use of prescribed medications or illicit drugs20 were expected. Although major disruptions in CP management were anticipated by the research and the clinical communities,14,16,19,23,24,33,35,40,53,57,66 the impact of the pandemic among individuals living with CP still needed to be quantified.

This study aimed at documenting the impact of the COVID-19 pandemic on the pharmacological and physical/psychological management of CP. Participants' characteristics associated with changes in pain treatments during the pandemic were also examined.

2. Methods

2.1. Study design and sample

This study was part of a larger initiative, the Chronic Pain & COVID-19 Pan-Canadian Study,51 which used a web-based, cross-sectional, and mixed-method design to answer various research questions surrounding how CP patients experienced the pandemic. Individuals aged 18 years and older, living in Canada, reporting pain for more than 3 months,63 and able to complete a web-based self-administered questionnaire in French/English were eligible. The study was approved by the Centre hospitalier de l'Université de Montréal's Research Ethics Board. Patient partners were involved in every step of the study.

2.2. Web-based data collection

Data were collected with SurveyMonkey. A web-based recruitment strategy, which was shown as effective in previous studies,37,38 was implemented to reach a community sample of Canadian living with CP. The questionnaire's hyperlink that led potential participants to the landing page of the study where enough information was provided for informed consent was included in the invitation message.

The recruitment strategy included the following: (1) advertisement by national and provincial CP patient associations through their e-newsletter, social media page, and/or website, (2) invitations shared among various Facebook support groups related to CP or associated conditions, (3) email invitations and social media posts (Facebook and Twitter) shared by colleagues and friends from various socioeconomic statuses (snowballing technique), and (4) email invitations and social media posts shared by local, provincial, and national research networks. The study was also announced on the intranets and in press releases issued by the principal investigators' institutions and was subsequently covered in various broadcasts and text interviews published on the web. To maximize study participation, individuals who completed the questionnaire were offered the possibility to enter a draw to win 1 of 10 $100 prepaid gift cards. Multiple participations from the same person were minimized by the survey platform. The questionnaire was pretested by 5 French-speaking and English-speaking individuals living with CP with various levels of education.

The study was open from April 16 to May 31, 2020, roughly 1 month after a state of emergency was declared in most Canadian provinces; the first province to declare a state of emergency was Quebec on March 12th, and the last one was Nova Scotia on March 22nd.7 The questionnaire was available when the cumulative cases of the first COVID-19 pandemic wave were growing exponentially in some provinces (ie, in Quebec, Ontario, and Alberta) and during the peak of daily reported new cases in Canada.26 The recruitment was stopped when announcements for some loosening up of the public health safety restrictions were being made.

2.3. Study Variables

Changes in pharmacologic pain treatments were assessed using a close-ended question (“did you modify your pharmacological treatments for pain because of the COVID-19 pandemic? [eg, opioids, anti-inflammatories, or any other prescribed or over-the-counter medications]”), followed by the answers “yes,” “no,” and “not applicable because I do not take any pain medications.” A similar question was presented for physical/psychological treatments. Participants who answered “yes” were asked to explain why and how they had modified their treatments using an open-ended question. This question format was chosen because of the exploratory nature of this study and the aim of collecting more insights and a wider range of responses. The reasons collected (verbatim) were reviewed individually to develop a standardized coding system. Coding was then achieved independently by 2 authors who reached consensus for any nonconcordance afterwards. Other variables covered in the web-based questionnaire are presented in Table 1.

Table 1 - Covariables measured in the web-based questionnaire.
Pain characteristics Items covered pain duration, pain frequency, body location (including presence of generalized pain or multisite pain defined as ≥2 body sites), intensity (0–10 numerical rating scales for average pain intensity in the past 7 d and when pain was at its worst in the past 7 days21,34), and unpleasantness (0–10 numerical rating scale for average pain unpleasantness in the past 7 days21). Pain interference in the past 7 days was assessed with the Brief Pain Inventory (BPI).15 Participants were also asked information about their primary pain care provider.
COVID-related variables Changes in pain symptoms since the beginning of the pandemic was assessed using a 7-point Patient Global Impression of Change (PGIC)21 scale.
The questionnaire also assessed if participants had needed to renew their pain medication prescriptions since the beginning of the pandemic, if they had a confirmed or pending diagnosis of COVID-19 infection, current COVID-like symptoms, any contact with a person with confirmed or pending diagnosis in the past 30 days, if they had travelled outside Canada since January 2020, had their employment status changed during the pandemic, and if they consulted a specialized COVID-19 screening clinic in the past 2 weeks.
Finally, they reported their level of stress in relation to the pandemic on the question “on a scale from 0 (not at all) to 10 (extremely), to what extent do you find the COVID-19 pandemic stressful?”
General health Psychological distress symptoms in the past month was assessed with the anxiety/depression subscales of the Patient Health Questionnaire (PHQ-4),36 which allows for the classification of the total scores into severity groups.
Participants were also asked if a health care provider had told them that their immune system was weak or compromised. Self-perceived health was assessed with the EQ-5D-5L 0–100 item28 ranging from “worst health you can imagine” to “best health you can imagine.”
Sociodemographic profile Age, sex (female, male, and undetermined), race/ethnicity (statistics Canada's categories60), education, employment status before public health measures were first deployed in their province, current living arrangement, marital status, province of residence, and the first 3 characters of their postal code (allowing for an urban vs rural classification).
The dates of the questionnaire completion were used to classify participants within 7 categories representing the 7 calendar weeks during which the questionnaire was available.

2.4. Data analysis

Our study sample included the participants who completed the items about changes in pain treatments. Scores on pain characteristics which were measured at the very beginning of the questionnaire and which had very few missing data points were compared between participants who completed the items about changes in pain treatments vs those with missing data to detect any clinically significant differences (>20% differences22). Descriptive statistics were calculated to summarize the participants' characteristics, changes in pain treatments, and reasons behind the changes. Proportions of participants reporting changes in their pharmacological or physical/psychological treatments were stratified according to factors of interest such as the week during which the questionnaire was completed, sex, province of residence, and body location of pain symptoms.

Among users of pain medications, a multivariable logistic regression model was used to identify participants' characteristics associated with changes in pharmacologic treatments during the pandemic (dependent variable). A similar model was achieved to identify participants' characteristics associated with changes in physical/psychological pain treatments. A broad set of a priori determined variables potentially associated with such changes were included in the multivariable logistic regression models. Choice of variables was based on the existing scientific literature and/or clinical plausibility, as well as on the predisposing, enabling, and need factors proposed in Andersen's model (1995),1 a widely used model in health care utilization studies.2 Variance inflation factors were used to help detect and remove variables with multicollinearity (variance inflation factors < 565).

3. Results

Between April 16 and May 31, 2020, a total of 3428 individuals from all over Canada accessed the web-based questionnaire and 3159 participants living with CP ultimately met inclusion criteria (167 individuals reporting pain for less than 3 months and 102 with missing data regarding pain duration were excluded). Our sample was composed of the 2864 participants who shared their treatment experience. No clinically significant differences were found between those who answered the questions about changes in their treatments vs those who did not in terms of pain duration (47.2% vs 42.2% reporting pain for >10 years), pain frequency (92.3% vs 81.9% experiencing pain continuously), and presence of generalized pain (34.6% vs 26.4%). However, a greater proportion of participants included in this study reported multisite pain (92.9% vs 65.1%).

Characteristics of the study participants are presented in Table 2. Age ranged from 18 to 99 years (mean: 49.7 ± 13.7), and 83.5% were women. Undetermined sex was reported by 11 participants (0.41%). A large majority reported using pharmacological pain treatments (88.4%) and physical/psychological pain treatments (87.3%). Only 24 participants (0.9%) had been diagnosed with COVID-19 at the time of questionnaire completion.

Table 2 - Sociodemographic and clinical characteristics of the participants.
Characteristics (n = 2864) n (%)*
Age (y), mean ± SD 49.74 ± 13.69
Sex
 Females 2218 (83.51)
 Males 427 (16.08)
 Undetermined 11 (0.41)
Race/ethnicity
 White 2346 (88.33)
 Others 310 (11.67)
Postsecondary education
 Yes 2164 (82.22)
 No 468 (17.78)
Employed full-time or part-time before public health measures were first deployed in their province
 Yes 976 (34.99)
 No 1813 (65.01)
Province of residence
 Quebec 1221 (46.66)
 Ontario 622 (23.77)
 British Columbia 560 (21.40)
 Alberta 76 (2.90)
 Nova Scotia 41 (1.57)
 New Brunswick 25 (0.96)
 Manitoba 24 (0.92)
 Saskatchewan 22 (0.84)
 Newfoundland and Labrador 18 (0.69)
 Prince Edward Island 7 (0.27)
 Yukon 1 (0.04)
 Northwest Territories/Nunavut 0 (0.00)
Pain duration
 ≤2 y 354 (12.36)
 3–5 y 509 (17.77)
 5–10 y 649 (22.66)
 >10 y 1352 (47.21)
Experience pain continuously
 Yes 2638 (92.30)
 No 220 (7.70)
Pain intensity on average in the past 7 days (0–10)—mean ± SD 6.13 ± 1.84
Use of pharmacological pain treatments
 Yes 2533 (88.44)
 No 331 (11.56)
Use of physical/psychological pain treatments
 Yes 2467 (87.27)
 No 360 (12.73)
Change in pain symptoms since the beginning of the pandemic
 Considerably worsened/worsened a lot/somewhat worsened 1974 (69.02)
 Unchanged 742 (25.94)
 Somewhat improved/improved a lot/considerably improved 144 (5.03)
Needed to renew pain medication since the beginning of the pandemic
 Yes 1621 (64.27)
 No 901 (35.73)
Diagnosis of COVID-19 confirmed by a test
 Yes 24 (0.85)
 No 2797 (99.15)
*Unless stated otherwise.

In the subsample of users of prescribed or over-the-counter pain medications (n = 2533), 38.3% reported changes in their pharmacological treatments during the pandemic. Among those participants, 40.5% reported COVID-related reasons, 57.11% non–COVID-related reasons (even if participants were asked explicitly about modifications made to their treatments because of the pandemic), and 2.4% no specific reason. COVID-related reasons for changes in pharmacological pain treatments during the pandemic are presented in Figure 1. The most common reasons were as follows: (1) change in pain symptoms because of the pandemic, (2) lack of access to prescribers, including cancellation of medical appointments or closed clinics, and (3) increase in medication intake in compensation for the stop of physical/psychological approaches. Among participants who used physical/psychological pain management approaches (n = 2467), 68.3% reported that they modified their treatments or self-management strategies during the pandemic. In this subsample, 83.6% reported COVID-related reasons, 15.6% non–COVID-related reasons, and 0.8% no specific reason. Common COVID-related reasons reported by participants (Figure 2) were lack of access to clinics/exercise installations or the need to change in compensation for stopping another type of physical/psychological treatments because of the pandemic. Few participants reported fear of going out or financial issues as reasons why changes were brought to their pharmacological or physical/psychological treatments. When looking at the week of questionnaire completion, the proportion of participants reporting changes in their pharmacological treatments was stable in time whereas changes in physical/psychological treatments appeared to be more common later during the pandemic (Figure 3). More women than men reported changes in their treatments (Figure 4). The percentage of participants reporting having modified their treatments seemed to vary substantially according to the province of residence (Figure 5), but not according to the body location of pain symptoms (Figure 6).

F1
Figure 1.:
COVID-related reasons why participants reported having changed their pharmacological pain treatments during the pandemic. *Categories are not mutually exclusive because participants could list various reasons; N.B. 577 of the 970 participants who reported changes in their pain medication (59.48%) did not provide any specific reason (2.37%) or reasons not related to the COVID-19 pandemic (57.11%) –e.g., drug side effects and litigation with insurance company (data not shown in the graph).
F2
Figure 2.:
COVID-related reasons why participants reported having changed their physical/psychological pain treatments during the pandemic. *Categories are not mutually exclusive since participants could list various reasons; N.B. 277 of the 1685 participants who reported changes in their physical/psychological pain treatments (16.44%) did not provide any specific reason (0.83%) or reasons not related to the COVID-19 pandemic (15.61%) (data not shown in the graph).
F3
Figure 3.:
Proportions of participants having reported changes in their pharmacological or physical/psychological pain treatments during the pandemic according to the week of questionnaire completion.
F4
Figure 4.:
Proportions of participants having reported changes in their pharmacological or physical/psychological pain treatments during the pandemic according to sex.
F5
Figure 5.:
Proportions of participants having reported changes in their pharmacological (upper panel) or physical/psychological treatments (lower panel) during the pandemic according to province of residence. QC: Quebec, BC: British Columbia, AB: Alberta, SK: Saskatchewan, MB: Manitoba, ON: Ontario, NB: New Brunswick, NS: Nova Scotia, PEI: Prince Edward Island, NL: Newfoundland and Labrador, YK: Yukon; PEI (n = 7), NL (n = 18), and YK (n = 1) were grouped because of the small sample size.
F6
Figure 6.:
Proportions of participants having reported changes in their pharmacological or physical/psychological pain treatments during the pandemic according to the body location of pain symptoms. *Categories are not mutually exclusive since participants could list various body locations.

Results of the multivariable model used to identify participants' characteristics associated with changes in pharmacological pain treatments during the pandemic are presented in Table 3. The model included 61 dummy variables. Independent of other characteristics included in the model, 9 factors were found to be associated with an increased likelihood of pharmacological treatment modification: (1) change in pain symptoms since the beginning of the pandemic (OR worsened vs unchanged: 3.84, 95% confidence interval [CI]: 2.92–5.06; OR improved vs unchanged: 2.76, 95% CI: 1.65–4.62), (2) having needed to renew pain medication during the pandemic (OR: 1.79, 95% CI: 1.45–2.22), (3) not being followed in a family medicine group (FMG) for pain treatment (OR private clinic vs FMG: 1.91, 95% CI: 1.18–3.09; OR not receiving pain care vs FMG: 1.95, 95% CI: 1.31–2.90; OR other pain treatment vs FMG group: 1.39, 95% CI: 1.07–1.81; no difference regarding pain clinic vs FMG), (4) employment status change during the pandemic (OR miscellaneous status change vs continue to work and have to commute to work: 2.08, 95% CI: 1.30–3.34), (5) change in physical/psychological treatments during the pandemic (OR: 2.18, 95% CI: 1.71–2.78), (6) presence of psychological distress symptoms in the past month (OR severe vs none: 1.75, 95% CI: 1.21–2.54), (7) having a postsecondary education (OR: 1.36, 95% CI: 1.04–1.78), (8) being employed before the pandemic (OR: 1.56, 95% CI: 1.06–2.28), and (9) province of residence (OR British Columbia vs Quebec: 1.42, 95% CI: 1.02–1.96). Variables associated with a decreased likelihood of a change in pharmacological pain treatments during the pandemic were as follows: (1) reporting generalized pain (OR: 0.73, 95% CI: 0.58–0.90) and (2) week of questionnaire completion (OR week 6 vs week 1: 0.55, 95% CI: 0.33–0.90).

Table 3 - Results of the multivariable logistic regression models used to identify participants' characteristics associated with changes in pain treatments during the pandemic.
Treatment users' characteristics* Adjusted results regarding factors associated with changes in pharmacological pain treatments Adjusted results regarding factors associated with changes in physical/pharmacological pain treatments
OR 95% confidence interval P OR 95% confidence interval P
Pain characteristics
 Pain duration (vs ≤2 y)
  3–5 y 0.829 0.565–1.216 0.3363 0.973 0.631–1.501 0.9025
  5–10 y 0.946 0.659–1.358 0.7622 0.899 0.597–1.353 0.6093
  >10 y 0.995 0.706–1.401 0.9758 0.923 0.628–1.356 0.6829
 Experience pain continuously (yes vs no) 0.848 0.556–1.293 0.4430 1.145 0.717–1.826 0.5710
 Received a medical diagnosis for his/her pain (yes vs no) 0.877 0.628–1.224 0.4405 1.363 0.935–1.986 0.1075
 Multisite pain (yes vs no) 1.238 0.776–1.976 0.3705 1.520 0.945–2.445 0.0842
 Generalized pain (yes vs no) 0.726 0.5830.904 0.0042 1.163 0.904–1.497 0.2400
 Pain intensity on average in the past 7 days (0–10) 1.011 0.938–1.091 0.7674 0.915 0.841–0.996 0.0393
 BPI interference score (0–10) 1.033 0.957–1.115 0.4027 1.041 0.957–1.132 0.3490
 Primary pain care provider (vs family medicine group)
  Others 1.393 1.0741.805 0.0124 1.303 0.967–1.755 0.0818
  Private clinic 1.912 1.1833.090 0.0082 0.848 0.502–1.432 0.5368
  Pain clinic 1.174 0.913–1.511 0.2109 1.254 0.944–1.665 0.1181
  Not receiving pain care 1.949 1.3092.902 0.0010 0.702 0.450–1.097 0.1202
COVID-related variables
 Change in pain symptoms since the beginning of the pandemic (vs unchanged)
  Worsened 3.843 2.9195.059 <0.0001 2.452 1.898–3.169 <0.0001
  Improved 2.757 1.6464.620 0.0001 3.404 1.801–6.435 0.0002
 Needed to renew pain medication since the beginning of the pandemic (yes vs no) 1.791 1.4452.220 <0.0001 1.067 0.843–1.351 0.5881
 Diagnosis of COVID-19 confirmed by a test (yes vs no) 0.689 0.219–2.166 0.5233 0.759 0.222–2.592 0.6598
 Waiting for a test or the results of a diagnostic test (yes vs no) 1.298 0.427–3.944 0.6457 0.541 0.164–1.780 0.3117
 Currently having symptoms (cough and fever) that could be caused by COVID-19 (yes vs no) 1.166 0.661–2.056 0.5953 0.868 0.455–1.657 0.6682
 Have been in physical contact or in proximity (less than 2 metres) with a person who has been diagnosed with COVID-10 or waiting for test results in the past 30 days (yes vs no) 0.878 0.505–1.529 0.6469 0.759 0.410–1.404 0.3795
 Have travelled outside Canada since January 2020 (yes vs no) 1.067 0.802–1.419 0.6573 1.029 0.741–1.431 0.8629
 Employment status during pandemic (vs continue to work and have to commute to work)
  Continued to work but remotely 1.202 0.790–1.829 0.3904 1.430 0.898–2.276 0.1319
  Temporarily laid off 0.944 0.580–1.539 0.8185 1.651 0.969–2.814 0.0654
  Permanently laid off 1.059 0.342–3.279 0.9213 1.061 0.361–3.118 0.9137
  Temporary return to work to help during the crisis 0.286 0.030–2.750 0.2782 0.456 0.089–2.332 0.3453
  No change/not working 1.636 0.980–2.732 0.0599 1.005 0.563–1.793 0.9860
 Other/miscellaneous status changes 2.082 1.3003.335 0.0023 1.447 0.839–2.495 0.1838
 Consulted in a specialized screening clinic for COVID-19 over the past 2 weeks (yes vs no) 1.153 0.673–1.977 0.6040 0.976 0.522–1.823 0.9386
 Change in physical/psychological pain treatments during the COVID-19 pandemic (change in pharmacological pain treatments during the COVID-19 pandemic for the second model)
  Yes (vs no) 2.179 1.7082.780 <0.0001 2.187 1.710–2.798 <0.0001
  Not applicable (vs no) 2.114 1.4823.016 <0.0001 0.858 0.078–9.379 0.9000
  Stress towards the pandemic (0–10) 0.998 0.951–1.047 0.9238 1.000 0.947–1.055 0.9921
General health
 Psychological distress symptoms according to the PHQ-4 (vs none)
  Mild 1.198 0.896–1.602 0.2220 0.713 0.519–0.978 0.0359
  Moderate 1.369 0.987–1.901 0.0602 0.853 0.588–1.237 0.4023
  Severe 1.750 1.2082.537 0.0031 0.601 0.394–0.915 0.0176
 Was told by a health care provider that his/her immune system was weak or compromised 1.017 0.826–1.252 0.8753 0.840 0.663–1.064 0.1486
 Self-perceived health according to the EQ-5D-5L (0–100) 1.003 0.998–1.009 0.2300 1.000 0.994–1.006 0.9066
Sociodemographic profile
 Age (y) 0.997 0.988–1.006 0.5121 0.980 0.970–0.990 0.0001
 Sex (females vs males/undetermined) 1.177 0.882–1.570 0.2677 1.752 1.304–2.354 0.0002
 Race/ethnicity (white vs others) 0.915 0.666–1.257 0.5838 1.359 0.954–1.936 0.0891
 Postsecondary education (yes vs no) 1.360 1.0371.783 0.0262 2.093 1.578–2.775 <0.0001
 Employed full-time or part-time at the time public health measures were first deployed in their province (yes vs no) 1.558 1.0642.279 0.0226 0.688 0.439–1.081 0.1045
 Disabled at the time public health measures were first deployed in their province (yes vs no) 0.917 0.709–1.186 0.5095 1.128 0.847–1.501 0.4103
 Living alone (yes vs no) 0.955 0.701–1.302 0.7719 1.330 0.946–1.871 0.1012
 Marital status (vs married/common law)
  Single 0.893 0.667–1.197 0.4493 0.562 0.406–0.779 0.0005
  Separated or divorced 1.182 0.848–1.648 0.3237 0.541 0.374–0.781 0.0011
  Widowed 0.973 0.520–1.820 0.9308 0.607 0.312–1.182 0.1419
 Province (vs Quebec)
  British Columbia 1.415 1.0241.955 0.0355 2.296 1.564–3.370 <0.0001
  Alberta 0.973 0.534–1.774 0.9282 2.747 1.297–5.820 0.0083
  Saskatchewan 2.479 0.762–8.061 0.1312 1.628 0.439–6.038 0.4663
  Manitoba 2.483 0.891–6.920 0.0819 1.143 0.370–3.533 0.8165
  Ontario 1.173 0.875–1.572 0.2850 0.947 0.691–1.296 0.7326
  New Brunswick 0.437 0.133–1.437 0.1727 3.155 0.819–12.147 0.0948
  Nova Scotia 0.692 0.312–1.533 0.3643 2.655 0.952–7.409 0.0622
  Prince Edward Island/Newfoundland and Labrador/Yukon 1.086 0.403–2.922 0.8706 2.036 0.620–6.688 0.2413
 Residing in a rural area (vs urban) 1.193 0.902–1.578 0.2171 0.900 0.660–1.227 0.5050
 Week of questionnaire completion (vs week 1)
  Week 2–April 20–26 0.833 0.597–1.164 0.2855 1.181 0.815–1.710 0.3796
  Week 3–April 19–May 3 0.820 0.552–1.218 0.3255 1.119 0.725–1.727 0.6121
  Week 4–May 4–10 0.752 0.488–1.159 0.1964 1.036 0.640–1.675 0.8863
  Week 5–May 11–17 0.769 0.488–1.212 0.2572 1.144 0.686–1.907 0.6069
  Week 6–May 18–24 0.545 0.3300.900 0.0177 1.125 0.645–1.965 0.6776
  Week 7–May 25–31 0.753 0.430–1.319 0.3210 1.279 0.661–2.477 0.4652
Bold text indicates statistically significant associations (95% confidence interval that excludes 1/P-value less than 0.05).
*2135 and 1903 participants were included in the first and the second multivariate analysis, respectively.
Too few participants reported underdetermined sex/gender identity (n = 11), so they were combined with men for the analysis.
The province of Quebec was chosen as the reference category because it was the most severely affected in terms of number of COVID-19 cases and deaths.
BPI, Brief Pain Inventory; PHQ-4, Patient Health Questionnaire—4 items.

Results of the multivariable model used to identify participants' characteristics associated with changes in physical/psychological pain treatments are also presented in Table 3. Variables associated with an increased likelihood of physical/psychological treatment modification were as follows: (1) change in pain symptoms since the beginning of the pandemic (OR worsened vs unchanged: 2.45, 95% CI: 1.90–3.17; OR improved vs unchanged: 3.40, 95% CI: 1.80–6.44), (2) change in pharmacological treatments during the pandemic (OR: 2.19, 95% CI: 1.71–2.80), (3) being a female (OR: 1.75, 95% CI: 1.30–2.35), (4) having a postsecondary education (OR: 2.09, 95% CI: 1.58–2.78), and (5) province of residence (OR British Columbia vs Quebec: 2.30, 95% CI: 1.56–3.37; OR Alberta vs Quebec: OR: 2.75, 95% CI: 1.30–5.82). Factors associated with a decreased likelihood of a change in physical/psychological pain treatments during the pandemic were as follows: (1) higher average pain intensity in the past 7 days (OR: 0.92, 95% CI: 0.84–0.996), (2) presence of psychological distress symptoms in the past month (OR mild vs none: 0.713, 95% CI: 0.52–0.98; OR severe vs none: 0.60, 95% CI: 0.39–0.92), (3) older age (years) (OR: 0.98, 95% CI: 0.97 0.99), and (4) being single, separated, or divorced (OR single vs married/common law: 0.56, 95% CI: 0.41–0.78; OR separated or divorced vs married/common law: 0.54, 95% CI: 0.37–0.78).

4. Discussion

This study aimed to quantify the impact of the COVID-19 pandemic on the management of CP from the perspective of Canadians living with this condition. When just over a third of participants experienced changes in their pharmacological treatments, changes in physical and psychological approaches were the most important with 7 of 10 participants reporting such disruptions. Lack of access to clinics and exercise facilities was an important driver, and many participants needed to compensate for having to stop their usual treatments. Various sociodemographic and clinical factors were associated with the likelihood of experiencing changes in pain treatments during the pandemic.

In response to the COVID-19 pandemic, clinical practice recommendations have been rapidly issued by expert panels in the field of CP management.16,19,57 However, the research community was urged to produce epidemiological data that could help characterize the impact of the pandemic among individuals living with CP and inform interventions to reduce its effects.14 Data collection that can inform risk and/or management of drug shortages and assessment of the impact of the COVID-19 crisis on health care utilization and outcomes for non–COVID-19 diseases were identified as research priorities.55 To the best of our knowledge, the present Pan-Canadian study is the first of its kind to quantify the impact of the pandemic on the pharmacological and physical/psychological treatments of CP.

4.1. Prevalence and reasons for changes in pain treatments

Disruptions in physical/psychological management approaches to CP were the most prevalent (68%). The fact that fewer participants were impacted in terms of their pharmacological treatments (38% reported changes during the pandemic and less than half of them reported COVID-related reasons for such changes) suggests that relatively effective measures were put in place for many patients (eg, deliveries from pharmacies, telemedicine, prescription prolongation, pharmacist extensions of controlled drug prescriptions, etc.). It should also be pointed out that 35.7% of them did not need to renew pain medication since the beginning of the pandemic. Surprisingly, drug shortages and uncertainties around the use of NSAIDs, which had been widely broadcast throughout the media, were reported only by a minority of participants (3.3% and 3.2%). Changes to pharmacological treatment approaches were nonetheless reported (eg, 8.7% reported increase of medication intake to compensate for stopping physical/psychological treatments because of the pandemic), and further research is needed to investigate this issue to identify other strategies that could be implemented in future instances of health crisis. Health care professionals could also draw on the existing literature about optimal pharmacological treatments after natural disasters to identify new avenues45,49

As for physical/psychological treatments, the impact of the pandemic is deplorable because those approaches are often hard to implement and maintain despite their importance for pain management.3,12 Both our descriptive and multivariable results converge regarding the presence of an association between changes in pharmacological and physical/psychological treatments, which underline the importance of adopting the multimodal treatment paradigm10 in all interventions. As a lack of access to health care services and exercise facilities was the most common reason for changes in physical/psychological treatments during the pandemic, the development of interventions, policies, and knowledge transfer initiatives should target these problems. Practical recommendations for the rapid introduction of virtual interventions in response to the pandemic is already a hot topic in the field of pain management.23 Short videos suggesting alternatives when the usual physical/psychological treatments are not feasible could also be beneficial, and social media were suggested as useful dissemination tools in that regard.18,46

Incidental findings emerged from reading through the high number of verbatim answers. For example, some participants had to reintroduce or increase opioids despite tapering-off before the pandemic. Greater opioid requirements were indeed expected after exacerbation of pain symptoms in response to psychological stress brought by the pandemic57 and were reported in clinical settings.33,40 Other participants in our study reported using more cannabis products (medical or not) or even alcohol to ease their pain.

4.2. Changes in pain treatments and relations to clinical symptoms

Changes in pain condition since the beginning of the pandemic, pain intensity, and the presence of psychological distress symptoms were found to be significantly associated with change in pain treatments. Although the cross-sectional nature of the study affects the assessment of temporality between such variables, there are reasons to believe that changes in pharmacological and physical/psychological pain treatments resulted in symptoms degradation and not the opposite. First, because only a few participants (2.5%–11.6%) reported changes in their pain condition as the reason for pharmacological or physical/psychological treatment modification, we can presume that changes in pain treatments preceded modifications in pain symptoms. Second, even if both improvement and degradation of pain symptoms (as compared with unchanged symptoms) were associated with changes in pain treatments, only a minority of participants reported improvement of their pain condition in our study (5%). It is possible that the few participants who reported improvement of pain symptoms had success when switching to new treatment avenues (eg, positive lifestyle adjustments during confinement such as stretching and exercises at home every day with the family instead of attending weekly exercise classes).

4.3. Other factors associated with changes in pain treatments

Participants with generalized pain (for which the most likely reason is fibromyalgia27) were less likely to report changes in their pharmacological treatments. This association could be explain because their drug regimen may differ from that of patients with other types of pain conditions.43,44,58 In fact, trends in prescriptions dispensed before, during, and after the COVID-19 pandemic varied depending on the drug class64 and, as stated earlier, challenges surrounding access to some specific drug classes used in pain management arose during the pandemic. Participants who reported receiving pain care in a FMG were less likely to report changes in their pharmacological treatments than those treated in other clinical settings such as private clinics. Service continuity strategies used in such clinical settings should be further investigated. As expected, employment status changes during the pandemic and having needed to renew pain medication during this period were factors associated with changes in pharmacological pain treatments. Regardless of pain severity and all other variables included in our model, age and sex were both associated with the likelihood of reporting changes in physical/psychological pain treatments. This result could inform targeted prevention strategies of treatment disruptions and innovative treatment alternatives (eg, targeting females and young adults). Provincial differences were found in this study; as opposed to the province of Quebec, chances of reporting changes in pain treatments were increased in the provinces of British Columbia (as for pharmacological and physical/psychological treatments) and Alberta (as for physical/psychological pain treatments). Although Quebec was the most severely affected province in terms of the number of COVID-19 cases and deaths, all 3 provinces ranked in the top 4 of hot zones. Factors such as the variability in the public health responses of each province may explain this result.

4.4. SARS-CoV-2 and pain symptoms

The COVID-19 pandemic and associated public health measures have been identified as factors that could exacerbate symptoms of noninfected people living with CP (eg, lack of access to pain treatments and numerous/persistent stressors).14 One might also expect new onset of pain after SARS-CoV-2 infection and its complications (postviral syndrome),11,14 or even in healthy populations who experienced pandemic-related stress and risk factor exacerbation.14 At the preclinical level, some pain models suggested that SARS-CoV-2 infection could induce pain,61 whereas some data revealed possible pain relief.48 In our study, only 24 participants had been diagnosed with COVID-19, which limits our capacity to draw statistically valid conclusions about their experience, how the infection affected their pain, or the attention given to their pain when receiving COVID-related care. More large clinical studies are thus clearly needed.

4.5. Strengths and limitations

The core strengths of this study are its ability to capture data across multiple provinces in Canada and its capacity to do so during the peak of the first COVID-19 pandemic wave. Our study sample was comparable with previously described random surveys of individuals living with CP in terms of: (1) age (mean age: 49.7 vs 46.6–48.4),6,47,62 (2) proportion of workers (35% vs 38%–44%),6,47 (3) proportion of participants living with pain for more than 10 years (47.2% vs 46%–46.7%),6,56 and (4) pain intensity (mean 0–10 score: 6.1 ± 1.8 vs 6.3–6.9).5,47 The overrepresentation of women (83.5% vs 55%–65.3%5,6,47,62) is, however, a limitation of this study. This may be partly because of our web-based sampling method that favoured female participation as they are known to be more inclined to use Facebook13 or work in an online environment.42 Nevertheless, having achieved the recruited of a substantial number of men (n = 427) allowed us to stratify our main measures according to sex and adjust for sex in our multivariable models. Therefore, we believe that the participation bias was minimized.

It should be noted that the assessment of the reasons why and how participants modified their treatments was not standardized (open-ended questions). For the identification of variables associated with changes in pain treatments during the pandemic, the possibility of type II error was reduced because of the substantial sample sizes used in the multivariate models (n = 2135 and 1903). Nevertheless, our data did not permit the assessment of associations between changes in pain treatments and ethnic minority subgroups (too few representatives), income categories, or gender constructs (variables not prioritized in comparison with COVID-related items for the benefit of a shorter questionnaire), although such subgroup analyses were suggested relevant in the context of the COVID-19 pandemic after our study started.4,25,66 Overall, there is reason to believe that pain management challenges identified in this study may represent the situation of many patients living in countries where similar public health measures were applied. However, since the impacts seem to vary depending on participants' province of residence, the exact figures quantifying these impacts should be generalized with caution.

5. Conclusion

Our study highlights the significant impact the COVID-19 pandemic had, and probably continues having, on access to CP relief. The quantification of such an impact is essential to inform and prioritize interventions in prevision of future waves of the pandemic or ulterior similar disasters. A priority would be, of course, to maintain continuity of care for individuals suffering from CP despite the pandemic. Health care professionals and support groups organizations should implement virtual care options to supplement safe in-person care. Online interventions and knowledge transfer activities could also prioritize informing and empowering people living with CP regarding alternative physical/psychological approaches when the usual ones are not feasible. Let us not forget that the non-COVID challenges of CP management are still present10 and have been amplified by the COVID-19 health crisis. Harnessing the web could enhance treatment access for people living with CP well beyond the COVID-19 pandemic.

Disclosures

The authors have no conflicts of interest to declare.

Acknowledgments

The authors thank the Association Québécoise de la douleur chronique, the Pain BC Society, and the Canadian Arthritis Patient Alliance for their feedback on the study design and questionnaires, and for their recruitment efforts. The authors also want to thank all Facebook support groups who helped with the advertisement of our study. Special thanks to our patient partners, Camille Fauteux, Jacques Laliberté, and Linda Wilhelm, for their insights and collaborations throughout the project. Ms. Emily-Jayn Rubec and Geneviève Lavigne, respectively, provided punctual translation and linguistic revision services.

The Chronic Pain & COVID-19 Pan-Canadian Study was funded by: (1) the Canadian Chronic Pain Network of the Canadian Institutes of Health Research through the Strategy for Patient-Oriented Research Program (grant # SCA-145102), (2) the Quebec Consortium on Adverse Effects of Pain Medications, an initiative funded by the Quebec Pain Research Network (QPRN) of the Fonds de recherche du Québec—Santé (FRQS), and (3) the Pain BC Society. M.G. Pagé and A. Lacasse are respectively Junior 1 and Junior 2 research scholars from the FRQS. The Chronic Pain Epidemiology Laboratory led by A Lacasse is funded by the Fondation de l'Université du Québec en Abitibi-Témiscamingue (UQAT), in partnership with local businesses: the Pharmacie Jean-Coutu de Rouyn-Noranda (community pharmacy) and Glencore Fonderie Horne (copper smelter). M. Hudspith, G. Moor, and K. Sutton are employees of the Pain BC Society, a charitable nonprofit organization working to enhance the well-being of people living with pain; the three of them were involved in the study design, participants' recruitment, and critical review of the article. All of the other funding sources had no role in the study design, collection, analysis and interpretation of data, writing of the manuscript, or decision to submit the article for publication.

Results of this study were presented at the: (1) Canadian Psychological Association Annual National Convention (virtual oral presentation), July 6–August 28, 2020, (2) Canadian Association for Population Therapeutics (CAPT) Annual Conference (virtual oral presentation), October 26–27, 2020. A brief abstract was published in the proceeding of the CAPT conference: Journal of Population Therapeutics and Clinical Pharmacology 2020;27:e31-e32.

References

[1]. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1–10.
[2]. Babitsch B, Gohl D, von Lengerke T. Re-revisiting andersen's behavioral model of health services use: a systematic review of studies from 1998-2011. Psychosocial Med 2012;9:Doc11.
[3]. Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. BMC Fam Pract 2017;18:41.
[4]. Borno HT, Zhang S, Gomez S. COVID-19 disparities: an urgent call for race reporting and representation in clinical research. Contemp Clin Trials Commun 2020;19:100630.
[5]. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: have we improved our management of chronic noncancer pain? Pain Res Manag 2007;12:39–47.
[6]. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. EurJ Pain 2006;10:287–333.
[7]. Bronca T. COVID-19: A Canadian timeline: Canadian healthcare Network. 2020. Available at: https://www.canadianhealthcarenetwork.ca/covid-19-a-canadian-timeline. Accessed August 21 2020.
[8]. Canada. Go. Coronavirus disease 2019 (COVID-19): Epidemiology update. Ottawa, ON: Government of Canada, 2020. Available at: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html.
[9]. Canada. PHAo. People who are at high risk for severe illness from COVID-19. Ottawa: Government of Canada, 2020. Available at: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/people-high-risk-for-severe-illness-covid-19.html.
[10]. Canadian Pain Task Force. Chronic pain in Canada: Laying a foundation for action. Ottawa: Health Canada, 2019.
[11]. Carfì A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603–5.
[12]. CATH. Access to and availability of non-pharmacological treatments for chronic non-cancer pain in Canada: An environmental scan. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), 2018.
[13]. CEFRIO. L'usage des médias sociaux au Québec. Enquête NETendances 2018;9:1-18.
[14]. Clauw DJ, Hauser W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. PAIN 2020;161:1694–7.
[15]. Cleeland CS. The brief pain inventory user guide. Houston: The University of Texas MD Anderson Cancer Center, 2009. Available at: https://www.mdanderson.org/content/dam/mdanderson/documents/Departments-and-Divisions/Symptom-Research/BPI_UserGuide.pdf.
    [16]. Cohen SP, Baber ZB, Buvanendran A, McLean BC, Chen Y, Hooten WM, Laker SR, Wasan AD, Kennedy DJ, Sandbrink F, King SA, Fowler IM, Stojanovic MP, Hayek SM, Phillips CR. Pain management best practices from multispecialty organizations during the COVID-19 pandemic and public health crises. Pain Med 2020;21:1331–46.
    [17]. Crosby JC, Heimann MA, Burleson SL, Anzalone BC, Swanson JF, Wallace DW, Greene CJ. COVID-19: a review of therapeutics under investigation. J Am Coll Emerg Physicians Open 2020;1:231–7.
    [18]. Cuello-Garcia C, Perez-Gaxiola G, van Amelsvoort L. Social media can have an impact on how we manage and investigate the COVID-19 pandemic. J Clin Epidemiol 2020;127:198–201.
    [19]. Deer TR, Sayed D, Pope JE, Chakravarthy KV, Petersen E, Moeschler SM, Abd-Elsayed A, Amirdelfan K, Mekhail N, Workgroup AC. Emergence from the COVID-19 pandemic and the care of chronic pain: guidance for the interventionalist. Anesth Analg 2020;131:387–94.
    [20]. Dietze PM, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: anticipated consequences and initial responses. Drug Alcohol Rev 2020;39:297–300.
    [21]. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, Immpact. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. PAIN 2005;113:9–19.
    [22]. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von ST, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–21.
    [23]. Eccleston C, Blyth FM, Dear BF, Fisher EA, Keefe FJ, Lynch ME, Palermo TM, Reid MC, Williams ACC. Managing patients with chronic pain during the COVID-19 outbreak: considerations for the rapid introduction of remotely supported (eHealth) pain management services. PAIN 2020;161:889–93.
    [24]. El-Tallawy SN, Nalamasu R, Pergolizzi JV, Gharibo C. Pain management during the COVID-19 pandemic. Pain Ther 2020;9:453–466.
    [25]. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11:29.
    [26]. Government of Canada. COVID-19 situational awareness dashboard. Canada: Government of Canada, 2020. Available at: https://health-infobase.canada.ca/covid-19/dashboard/?stat=num&measure=total&map=pt&f=true#a2. Accessed August 26 2020.
    [27]. Hauser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA. Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2017;2:e598.
    [28]. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
    [29]. INESSS. COVID-19 et anti-inflammatoires non stéroïdiens [COVID-19 and nonsteroidal anti-inflammatory drugs]. Quebec: Institut national d'excellence en santé et en services sociaux (INESSS), 2020. Available at: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_Anti-inflammatoires.pdf. Accessed March 31 2020.
    [30]. INESSS. COVID-19 et pénurie de sédatifs, analgésiques et bloqueurs neuromusculaires [COVID-19 and shortage of sedatives, analgesics and neuromuscular blockers]. Quebec: Institut national d'excellence en santé et en services sociaux (INESSS), 2020. Available at: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_SedationSI_et_bloc.pdf. Accessed May 10 2020.
    [31]. INESSS. COVID-19 et ruptures d'inventaire de chloroquine et d'hydroxychloroquine [COVID-19 and chloroquine and hydroxychloroquine inventory breaks]. Quebec: Institut national d'excellence en santé et en services sociaux (INESSS), 2020. Available at: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_INESSS_ruptures_inventaire_chloroquine_hydroxychloroquine.pdf. Accessed April 1 2020.
    [32]. INSPQ. Ligne du temps COVID-19 au Québec [COVID-19 timeline in Quebec]. Quebec: Institut national de santé publique du Québec (INSPQ), 2020. Available at: https://www.inspq.qc.ca/covid-19/donnees/ligne-du-temps.
    [33]. Javed S, Hung J, Huh BK. Impact of COVID-19 on chronic pain patients: a pain physician's perspective. Pain Manag 2020;10:275–7.
    [34]. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, editors. Handbook of pain assessment. 2nd ed. New York: Guilford Press, 2001. p. 15–34.
      [35]. Karos K, McParland JL, Bunzli S, Devan H, Hirsh A, Kapos FP, Keogh E, Moore D, Tracy LM, Ashton-James CE. The social threats of COVID-19 for people with chronic pain. PAIN 2020;161:2229–35.
      [36]. Kroenke K, Spitzer RL, Williams JB, Lowe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009;50:613–21.
      [37]. Lacasse A, Choiniere M, Connelly JA. Knowledge, beliefs, and attitudes of the Quebec population toward chronic pain: where are we now? Can J Pain 2017;1:151–60.
      [38]. Lacasse A, Gagnon V, Nguena Nguefac HL, Gosselin M, Pagé MG, Blais L, Guénette L. Chronic pain patients' willingness to share personal identifiers on the web for the linkage of medicoadministrative claims and patient-reported data: The COPE Cohort. 2020. Submitted to Pharmacoepidemiology and Drug Safety on August 26, 2020.
      [39]. Lambert DG. Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability? Br J Anaesh 2020;125:e382–3.
      [40]. Lynch ME, Williamson OD, Banfield JC. COVID-19 impact and response by Canadian pain clinics: a national survey of adult pain clinics. Can J Pain 2020;4:204–9.
      [41]. Mahase E. Covid-19: demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ 2020;369:m2512.
      [42]. Marshall K. Utilisation de l'ordinateur au travail. L'emploi et le revenu en perspective. - L'édition en ligne 2001;2.
      [43]. Mathieson S, Wertheimer G, Maher CG, Christine Lin C-W, McLachlan AJ, Buchbinder R, Pearson SA, Underwood M. What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and meta-regression of observational studies. J Intern Med 2020;287:458–74.
      [44]. McDonagh MS, Selph SS, Buckley DI, Holmes RS, Mauer K, Ramirez S, Hsu FC, Dana T, Fu R, Chou R. Nonopioid Pharmacologic Treatments for Chronic Pain [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2020 Apr. (Comparative Effectiveness Review, No. 228.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK556277/.
      [45]. Melin K, Rodriguez-Diaz CE. Community pharmacy response in the aftermath of natural disasters: time-sensitive opportunity for research and evaluation. J Prim Care Community Health 2018;9:2150132718813494.
      [46]. Merchant RM, Lurie N. Social media and emergency preparedness in response to novel coronavirus. JAMA 2020;323:2011–2.
      [47]. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada—prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002;7:179–84.
      [48]. Moutal A, Martin LF, Boinon L, Gomez K, Ran D, Zhou Y, Stratton HJ, Cai S, Luo S, Gonzalez KB, Perez-Miller S, Patwardhan A, Ibrahim MM, Khanna R. SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia. PAIN 2021;162:243–52.
      [49]. Narayanan N, Lacy CR, Cruz JE, Nahass M, Karp J, Barone JA, Hermes-DeSantis ER. Disaster preparedness: biological threats and treatment options. Pharmacotherapy 2018;38:217–34.
      [50]. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 2020;78:185–93.
      [51]. Pagé MG, Lacasse A, Dassieu L, Hudspith M, Moor G, Sutton K, Thompson JM, Dorais M, Janelle Montcalm A, Sourial N, Choinière M. A cross-sectional study of pain status and psychological distress among individuals who live with chronic pain during the COVID-19 pandemic: the chronic pain & COVID-19 pan-Canadian study. Health Promot Chronic Dis Prev Can 2021;4 [In Press]
      [52]. Patel JA, Nielsen FBH, Badiani AA, Assi S, Unadkat VA, Patel B, Ravindrane R, Wardle H. Poverty, inequality and COVID-19: the forgotten vulnerable. Public health 2020;183:110–11.
      [53]. Pope JE. What does the COVID-19 pandemic mean for rheumatology patients? Curr Treatm Opt Rheumatol 2020:1–4.
      [54]. Rajkumar RP. COVID-19 and mental health: a review of the existing literature. Asian J Psychiatr 2020;52:102066.
      [55]. Reagan-Udall Foundation for the FDA, Friends of Cancer Research. COVID-19 evidence accelerator: Click here for summary of key questions and core data elements. Washington. Reagan-Udall Foundation for the Food and Drug Administration (FDA) in collaboration with Friends of Cancer Research (Friends) 2020. Available at: https://friendsofcancerresearch.org/covid19 Accessed September 29 2020.
      [56]. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag 2011;16:445–50.
      [57]. Shanthanna H, Strand NH, Provenzano DA, Lobo CA, Eldabe S, Bhatia A, Wegener J, Curtis K, Cohen SP, Narouze S. Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. Anaesthesia 2020;75:935–44.
      [58]. Singh JA, Cleveland JD. Time-trends in opioid use disorder hospitalizations in gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain. J Rheumatol 2020:jrheum.191370.
      [59]. Smart L, Fawkes N, Goggin P, Pennick G, Rainsford KD, Charlesworth B, Shah N. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020;28:1141–52.
      [60]. Statistics Canada. 2016 census of population questions, long form (national household survey). Government of Canada, 2015. Available at: https://www12.statcan.gc.ca/nhs-enm/2016/ref/questionnaires/questions-eng.cfm. Accessed July 7 2016.
        [61]. Su S, Cui H, Wang T, Shen X, Ma C. Pain: a potential new label of COVID-19. Brain Behav Immun 2020;87:159–60.
        [62]. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10:918–29.
        [63]. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). PAIN 2019;160:19–27.
        [64]. Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O'Donnell CJ, Warraich HJ. Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States. JAMA 2020;323:2524–6.
        [65]. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale) 2016;6:227.
        [66]. Webster F, Connoy L, Sud A, Pinto AD, Katz J. Grappling with chronic pain and poverty during the COVID-19 pandemic. Can J Pain 2020;4:125–8.
        Keywords:

        Chronic pain; COVID-19; Pain management; Web-based cross-sectional study

        Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.